Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,currency,market,shortName,exchange,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,exchangeDataDelayedBy,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry
t0,VSC.DE,33974000.0,50570000,4612000,,-4339000,,-4339000,666500,865000,-4413500,-4413500,,-8000,,,,0,1025500,5439000,160500,74500,,-4339000,-4339000,3472000.0,192282000.0,5016000.0,37446000.0,2134000.0,42462000.0,50570000.0,24000.0,-210359000.0,23000.0,4953000.0,183000.0,24203000.0,3682000.0,4953000.0,2062000.0,36745000.0,12000000.0,377000.0,895000.0,6250000,96500,6239500,-53500,3675000,1122500,3770000,6769000,-3145500,-87000,17500,-41500,-307000,-10500,33063000.0,en-US,US,EQUITY,False,Delayed Quote,5.03,1630566589,-0.1699996,5.02,5.03,5.02,330,0.74,6.0657144,-1.0357141,-0.17074892,7.6464787,-2.6164784,-0.34218085,254367104,-9.145454,6.7972975,15,Europe/Berlin,CEST,False,False,EUR,de_market,4SC AG INH. O.N.,GER,REGULAR,2,-3.2692232,5.02 - 5.03,5.2,5.03,5.19,500,2726,finmb_136709,XETRA,4SC AG,EUR,1362,2588,0.010000229,0.0019920776,5.02 - 11.45,-6.4199996,-0.5606987,5.02,11.45,1628593140,1634538600,0,1634884200,-0.41,-0.55,7200000,1.04,,,11.45,5.02,6.07,7.65,1.36k,2.59k,50.57M,,11.28M,67.31%,3.04%,,,,,,,,,,,0.00%,,,1:5,"Jul 19, 2021","Dec 31, 2020","Dec 31, 2020",0.00%,-868.61%,-25.63%,-44.35%,2.25M,0.05,"1,135.50%",1.73M,-19.42M,-18.99M,-0.41,,36.2M,0.72,1.56M,4.17,9.98,0.74,-15.69M,-9.95M,Value,82152,Healthcare,33,"4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.",Planegg,49 89 700763 0,1577750400,Germany,http://www.4sc.de,86400,Fraunhoferstrasse 22,49 89 700763 29,Biotechnology
t-1,VSC.DE,33974000.0,50570000,4612000,,-4339000,,-4339000,666500,865000,-4413500,-4413500,,-8000,,,,0,1025500,5439000,160500,74500,,-4339000,-4339000,3472000.0,192282000.0,5016000.0,37446000.0,2134000.0,42462000.0,50570000.0,24000.0,-210359000.0,23000.0,4953000.0,183000.0,24203000.0,3682000.0,4953000.0,2062000.0,36745000.0,12000000.0,377000.0,895000.0,6250000,96500,6239500,-53500,3675000,1122500,3770000,6769000,-3145500,-87000,17500,-41500,-307000,-10500,33063000.0,en-US,US,EQUITY,False,Delayed Quote,5.03,1630566589,-0.1699996,5.02,5.03,5.02,330,0.74,6.0657144,-1.0357141,-0.17074892,7.6464787,-2.6164784,-0.34218085,254367104,-9.145454,6.7972975,15,Europe/Berlin,CEST,False,False,EUR,de_market,4SC AG INH. O.N.,GER,REGULAR,2,-3.2692232,5.02 - 5.03,5.2,5.03,5.19,500,2726,finmb_136709,XETRA,4SC AG,EUR,1362,2588,0.010000229,0.0019920776,5.02 - 11.45,-6.4199996,-0.5606987,5.02,11.45,1628593140,1634538600,0,1634884200,-0.41,-0.55,7200000,1.04,,,11.45,5.02,6.07,7.65,1.36k,2.59k,50.57M,,11.28M,67.31%,3.04%,,,,,,,,,,,0.00%,,,1:5,"Jul 19, 2021","Dec 31, 2020","Dec 31, 2020",0.00%,-868.61%,-25.63%,-44.35%,2.25M,0.05,"1,135.50%",1.73M,-19.42M,-18.99M,-0.41,,36.2M,0.72,1.56M,4.17,9.98,0.74,-15.69M,-9.95M,Value,82152,Healthcare,33,"4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.",Planegg,49 89 700763 0,1577750400,Germany,http://www.4sc.de,86400,Fraunhoferstrasse 22,49 89 700763 29,Biotechnology
t-2,VSC.DE,34391000.0,50570000,4263000,,-4182000,,-4182000,731000,3000,-4991000,-4991000,,-9000,,,,0,52000,5043000,49000,809000,,-4182000,-4182000,3843000.0,189396000.0,5038000.0,38234000.0,2846000.0,43272000.0,45973000.0,1859000.0,-201681000.0,53000.0,4546000.0,123000.0,10665000.0,3548000.0,4546000.0,2230000.0,37076000.0,24500000.0,52000.0,702000.0,-5750000,-396000,-5760500,-70000,-72000,-136500,3770000,-10531000,-4698500,285500,-3000,-2000,706500,-10500,33528000.0,en-US,US,EQUITY,False,Delayed Quote,5.03,1630566589,-0.1699996,5.02,5.03,5.02,330,0.74,6.0657144,-1.0357141,-0.17074892,7.6464787,-2.6164784,-0.34218085,254367104,-9.145454,6.7972975,15,Europe/Berlin,CEST,False,False,EUR,de_market,4SC AG INH. O.N.,GER,REGULAR,2,-3.2692232,5.02 - 5.03,5.2,5.03,5.19,500,2726,finmb_136709,XETRA,4SC AG,EUR,1362,2588,0.010000229,0.0019920776,5.02 - 11.45,-6.4199996,-0.5606987,5.02,11.45,1628593140,1634538600,0,1634884200,-0.41,-0.55,7200000,1.04,,,11.45,5.02,6.07,7.65,1.36k,2.59k,50.57M,,11.28M,67.31%,3.04%,,,,,,,,,,,0.00%,,,1:5,"Jul 19, 2021","Dec 31, 2020","Dec 31, 2020",0.00%,-868.61%,-25.63%,-44.35%,2.25M,0.05,"1,135.50%",1.73M,-19.42M,-18.99M,-0.41,,36.2M,0.72,1.56M,4.17,9.98,0.74,-15.69M,-9.95M,Value,82152,Healthcare,33,"4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.",Planegg,49 89 700763 0,1577750400,Germany,http://www.4sc.de,86400,Fraunhoferstrasse 22,49 89 700763 29,Biotechnology
t-3,VSC.DE,43976000.0,50570000,4621500,,-5155000,,-5155000,751500,1500,-5367000,-5367000,-4500.0,-9500,,,,0,100500,5467500,99000,212000,,-5155000,-5155000,,,,48190000.0,,,,,,,,,,,,,,,,,-5750000,-396000,-5760500,-70000,-72000,-136500,3770000,-10531000,-4698500,285500,-3000,-2000,706500,-10500,,en-US,US,EQUITY,False,Delayed Quote,5.03,1630566589,-0.1699996,5.02,5.03,5.02,330,0.74,6.0657144,-1.0357141,-0.17074892,7.6464787,-2.6164784,-0.34218085,254367104,-9.145454,6.7972975,15,Europe/Berlin,CEST,False,False,EUR,de_market,4SC AG INH. O.N.,GER,REGULAR,2,-3.2692232,5.02 - 5.03,5.2,5.03,5.19,500,2726,finmb_136709,XETRA,4SC AG,EUR,1362,2588,0.010000229,0.0019920776,5.02 - 11.45,-6.4199996,-0.5606987,5.02,11.45,1628593140,1634538600,0,1634884200,-0.41,-0.55,7200000,1.04,,,11.45,5.02,6.07,7.65,1.36k,2.59k,50.57M,,11.28M,67.31%,3.04%,,,,,,,,,,,0.00%,,,1:5,"Jul 19, 2021","Dec 31, 2020","Dec 31, 2020",0.00%,-868.61%,-25.63%,-44.35%,2.25M,0.05,"1,135.50%",1.73M,-19.42M,-18.99M,-0.41,,36.2M,0.72,1.56M,4.17,9.98,0.74,-15.69M,-9.95M,Value,82152,Healthcare,33,"4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.",Planegg,49 89 700763 0,1577750400,Germany,http://www.4sc.de,86400,Fraunhoferstrasse 22,49 89 700763 29,Biotechnology
